A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer

In previously treated, unselected, advanced NSCLC patients, the addition of enzastaurin to erlotinib did not improve PFS, response, or OS compared with historical data of single-agent erlotinib, but was well tolerated.